STOCK TITAN
  1. Home
  2. Sec-filings
  3. OVID
  4. [EFFECT] Ovid Therapeutics Inc. SEC Filing

[EFFECT] Ovid Therapeutics Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: December 22, 2025 4:00 P.M.
Form: S-3
CIK: 0001636651
Company Name: Ovid Therapeutics Inc.
File Number: 333-292151

Source: View Original Filing on SEC EDGAR

Stock OVID logo
Ovid Therapeutics Inc

NASDAQ:OVID

OVID Rankings

#4789 Ranked by Market Cap
N/A Ranked by Dividends

OVID Latest News

Dec 18, 2025
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
Dec 2, 2025
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Nov 12, 2025
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Oct 3, 2025
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Oct 3, 2025
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

OVID Latest SEC Filings

Dec 18, 2025
[8-K] Ovid Therapeutics Inc. Reports Material Event
Dec 18, 2025
[Form 4] Ovid Therapeutics Inc. Insider Trading Activity
Dec 15, 2025
[S-3] Ovid Therapeutics Inc. Shelf Registration Statement
Nov 12, 2025
[10-Q] Ovid Therapeutics Inc. Quarterly Earnings Report
Nov 12, 2025
[8-K] Ovid Therapeutics Inc. Reports Material Event

OVID Stock Data

126.76M
58.50M
16.31%
34.69%
1.79%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK